Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Cytochromes P450 CYP2J and CYP2C Polyclonal Antibodies and Recombinant Proteins
Case ID:
TAB-2400
Web Published:
12/6/2022
The National Institutes of Health announces polyclonal antibodies against mouse cytochrome P450s CYP2J and CYP2C. Cytochrome P450s catalyze the metabolism of a wide range of exogenous compounds, including drugs, industrial chemicals, environmental pollutants, and carcinogens. The 2C family of cytochrome P450 metabolizes an extensive number of drugs which include tolbutamide, S-Warfarin, mephenytoin, diazepam and taxol. Many of the P450 enzymes are also active in the NADPH-dependent oxidation of arachidonic acid to various eicosanoids found in several species. The 2J family is expressed at high levels in the heart and has been shown to metabolize both arachidonic acid and linoleic acid. The CYP2J and CYP2C subfamily members have a wide tissue distribution and may be useful as model systems for studies of cardiovascular disease, drug metabolism and toxicity.
Recombinant proteins of mouse cytochrome P450s CYP2C and CYP2J have also been expressed and can be used as controls in immunoblotting, as well as for metabolism studies.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Direct Link:
https://canberra-ip.technologypublisher.com/tech/Cytochromes_P450_CYP2J_and_C YP2C_Polyclonal_Antibodies_and_Recombinant_Proteins
Keywords:
antibodies
CYP2C
CYP2J
CYTOCHROMES
IDXXXX
IXXXXX
P450
polyclonal
proteins
recombinant
Bookmark this page
Download as PDF
For Information, Contact:
Vidita Choudhry
Technology Development Specialist
NIH Technology Transfer
301-594-4095
vidita.choudhry@nih.gov